Solesence, Inc. Common Stock
Solesence, Inc., a science-driven company, develops, manufactures, and sells integrated family of technologies in the United States. The company engages in engineered materials, formulation development, and commercial manufacturing. It also provides skin care formulations with mineral-based UV protection enabled by proprietary active pharmaceutical ingredients under the Solésence brand; skin heal… Read more
Solesence, Inc. Common Stock (SLSN) - Net Assets
Latest net assets as of September 2025: $17.23 Million USD
Based on the latest financial reports, Solesence, Inc. Common Stock (SLSN) has net assets worth $17.23 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($53.99 Million) and total liabilities ($36.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.23 Million |
| % of Total Assets | 31.91% |
| Annual Growth Rate | 26.03% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 345.09 |
Solesence, Inc. Common Stock - Net Assets Trend (2021–2024)
This chart illustrates how Solesence, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Solesence, Inc. Common Stock (2021–2024)
The table below shows the annual net assets of Solesence, Inc. Common Stock from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $14.95 Million | +685.80% |
| 2023-12-31 | $1.90 Million | -66.33% |
| 2022-12-31 | $5.65 Million | -24.33% |
| 2021-12-31 | $7.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Solesence, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 298100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $700.00K | 4.68% |
| Other Components | $114.67 Million | 767.26% |
| Total Equity | $14.95 Million | 100.00% |
Solesence, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Solesence, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OYAK Yatirim Ortakligi AS
IS:OYAYO
|
$17.56 Million |
|
Hurriyet Gazetecilik ve Matbaacilik AS
IS:HURGZ
|
$17.56 Million |
|
V-Tac Technology Co Ltd
TWO:6229
|
$17.56 Million |
|
Nice D&B Co. Ltd
KQ:130580
|
$17.57 Million |
|
JMT Co.Ltd
KQ:094970
|
$17.55 Million |
|
UNITRAD
KLSE:0247
|
$17.55 Million |
|
George Kent (Malaysia) Bhd
KLSE:3204
|
$17.55 Million |
|
MEI Pharma Inc
NASDAQ:MEIP
|
$17.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Solesence, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,902,000 to 14,946,000, a change of 13,044,000 (685.8%).
- Net income of 4,235,000 contributed positively to equity growth.
- New share issuances of 6,000,000 increased equity.
- Other factors increased equity by 2,809,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.24 Million | +28.34% |
| Share Issuances | $6.00 Million | +40.14% |
| Other Changes | $2.81 Million | +18.79% |
| Total Change | $- | 685.80% |
Book Value vs Market Value Analysis
This analysis compares Solesence, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 6.07x to 4.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.16 | $0.96 | x |
| 2022-12-31 | $0.12 | $0.96 | x |
| 2023-12-31 | $0.04 | $0.96 | x |
| 2024-12-31 | $0.23 | $0.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Solesence, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 28.34%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.09%
- • Asset Turnover: 1.05x
- • Equity Multiplier: 3.35x
- Recent ROE (28.34%) is above the historical average (-54.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 31.08% | 7.87% | 1.04x | 3.80x | $1.57 Million |
| 2022 | -46.43% | -7.03% | 1.11x | 5.94x | $-3.19 Million |
| 2023 | -230.81% | -11.77% | 1.13x | 17.29x | $-4.58 Million |
| 2024 | 28.34% | 8.09% | 1.05x | 3.35x | $2.74 Million |
Industry Comparison
This section compares Solesence, Inc. Common Stock's net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $1,833,853,398
- Average return on equity (ROE) among peers: 27.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Solesence, Inc. Common Stock (SLSN) | $17.23 Million | 31.08% | 2.13x | $17.55 Million |
| Acme United Corporation (ACU) | $19.90 Million | 2.51% | 0.55x | $132.86 Million |
| Beiersdorf Aktiengesellschaft (BDRFF) | $3.02 Billion | 8.59% | 0.75x | $11.93 Billion |
| Science to Consumers Inc (BEUT) | $-3.05K | 0.00% | 0.00x | $1.09K |
| Société BIC SA (BICEY) | $1.70 Billion | 16.88% | 0.41x | $566.61 Million |
| Blue Moon Group Holdings Limited (BLUMY) | $12.35 Billion | 8.22% | 0.18x | $1.01 Billion |
| Bemax Inc (BMXC) | $-244.86K | 0.00% | 0.00x | $3.63K |
| Bruush Oral Care Inc. (BRSHF) | $-216.93K | 0.00% | 0.00x | $335.48 |
| Park Ha Biological Technology Co., Ltd. (BYAH) | $-578.18K | 0.00% | 0.00x | $11.97 Million |
| Church & Dwight Company Inc (CHD) | $284.43 Million | 16.52% | 2.34x | $22.97 Billion |
| Colgate-Palmolive Company (CL) | $971.00 Million | 223.07% | 14.49x | $67.85 Billion |